How Does ResMed Company Work?

How does ResMed deliver global respiratory and sleep-health solutions?

ResMed transformed from a device maker into a digital-health leader, reporting fiscal 2025 revenues above $5.1 billion and supporting over 170 million lives via cloud-connected therapy platforms. Its reach spans 140+ countries with dominant positions in OSA and COPD care.

ResMed pairs CPAP and ventilator hardware with software, cloud analytics and remote monitoring to create recurring revenue and value-based care partnerships. Its integrated ecosystem drives adherence, outcomes, and payer/provider integrations.

Explore competitive forces shaping the company: ResMed Porter's Five Forces Analysis

ResMed combines high-performance respiratory hardware with a cloud-based digital ecosystem to deliver clinical outcomes and lower total cost of care; its manufacturing hubs in Singapore and Australia support global distribution while platforms like AirView and myAir enable data-driven therapy management.

Device manufacturing and portfolio

Designs and manufactures CPAP, bilevel devices, and ventilators such as the AirSense 11 series, plus masks and accessories that drive therapy adherence and comfort.

Global production and logistics

Major production hubs in Singapore and Australia use advanced automation to sustain margins and meet regulatory quality standards across markets.

Digital health ecosystem

Cloud platforms like AirView for clinicians and myAir for patients connect devices for remote monitoring; over 18.5 million devices are cloud-connected, enabling proactive care.

SaaS and care workflows

Brands such as Brightree and MatrixCare provide SaaS workflow solutions for out-of-hospital care, expanding recurring revenue beyond device sales.

The integrated hardware-plus-software model is central to the ResMed company overview and ResMed business model, delivering measurable adherence and cost benefits that differentiate its market position.

Operational impact and metrics

Cloud-connected therapies significantly improve adherence and enable value-based care partnerships with providers and payers.

• Cloud-connected adherence: 87% vs ~50% for non-connected therapies
• Connected device footprint: > 18.5 million devices
• Key revenue mix: device sales plus growing SaaS/subscription and services streams
• Supply chain focus: centralized automated hubs for quality and margin control

For a historical perspective on the company and founding milestones see Brief History of ResMed

Complete ResMed Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

ResMed’s revenue model blends device sales, recurring consumables and SaaS subscriptions, with the Sleep and Respiratory Care segment driving the business through predictable hardware and resupply flows.

Segment concentration

As of fiscal 2025 the Sleep and Respiratory Care segment represents about 88% of total revenue, underpinning the ResMed company overview and reflecting core market strength.

Device sales mix

Device sales (CPAP/APAP) account for roughly 52% of revenue, using tiered pricing and premium features to raise average selling prices.

Consumables and masks

Masks and consumables contribute about 36% of revenue; automated resupply programs convert device buyers into recurring customers with high lifetime value.

SaaS and digital health

The SaaS out-of-hospital care business provides approximately 12% of revenue, offering subscription stability and recurring cash flow for ResMed's digital health strategy.

Geographic split

The U.S., Canada and Latin America deliver about 60% of total revenue, while other international markets provide the remaining 40%, shaping ResMed's market position.

Monetization levers

Key levers include tiered device pricing (cellular connectivity, AI coaching), automated consumable resupply, and subscription expansion into home-health management.

The company combines hardware-driven margins with software recurring revenue to smooth cyclicality; masks and consumables act as the central recurring engine while SaaS enhances gross margin resilience and customer retention.

Revenue mechanics

How ResMed works commercially: device introduction, data-enabled resupply, and subscription upsell across clinical and consumer channels, linking product and platform revenue.

• Device sales: ~52% of revenue from CPAP/APAP machines
• Consumables: ~36% from masks and resupply programs
• SaaS: ~12% from subscription out-of-hospital care services
• Geography: ~60% revenue from Americas; ~40% from other regions

Tiered pricing, automated resupply driven by patient-data triggers, and cross-selling of software to device users are the primary monetization strategies that increase ARPU and customer lifetime value; see a deeper commercial review in Marketing Strategy of ResMed.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

ResMed's key milestones include rapid market share gains after the 2021–2024 Philips Respironics recall, strategic acquisitions that expanded software reach, and a decisive pivot to cloud-connected card-to-cloud devices during global supply constraints.

Market share capture

Following the 2021–2024 Philips recall, ResMed increased production and captured incremental share, contributing to a device revenue uplift and a stronger market position in sleep therapy.

Supply-chain pivot

During the global semiconductor shortage, ResMed pivoted to card-to-cloud designs, enabling remote provisioning and reducing dependency on constrained components.

Software-driven growth

Acquisitions of Brightree (post-2016 integration) and MatrixCare (completed 2021–2022 integration phases) transformed ResMed into a leader in out-of-hospital software and recurring SaaS revenue.

Data and AI advantage

With billions of nights of anonymized sleep data in its cloud, ResMed applies machine learning to improve algorithmic accuracy, patient comfort, and adherence—strengthening its competitive moat.

ResMed's competitive edge rests on integrated hardware-plus-software, scale in cloud data, and strategic positioning versus hardware-only rivals.

Strategic moves and measurable outcomes

Key strategic moves produced quantifiable effects across revenue mix, market position, and clinical engagement.

• Revenue mix: higher recurring software and services share; ResMed reported software and cloud-connected services growth outpacing hardware in recent fiscal disclosures (software-run rates increasing into the low double digits percent of total revenue by 2024).
• Market position: captured excess demand after Philips Respironics recall, contributing to unit shipment growth and share gains in CPAP and non-invasive ventilation segments between 2021–2024.
• Clinical network effect: billions of nights of data improved diagnostic and therapy algorithms, enhancing value to clinicians and payors and raising switching costs for customers.
• GLP-1 interaction: 2025 internal research showed patients on GLP-1 therapies were more likely to seek OSA evaluation and maintain CPAP adherence, supporting incremental demand and payer engagement.

How ResMed works: the ResMed business model couples device sales with SaaS, cloud analytics, and care-management platforms to drive recurring revenue, higher lifetime value, and integrated care pathways for sleep and respiratory disorders. For context on competitors and market dynamics see Competitors Landscape of ResMed.

ResMed Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

ResMed holds a dominant position in sleep and respiratory care, with an estimated 60% share of the global flow generator market and leadership in cloud-connected devices; it leverages global distribution, brand equity, and recurring consumables revenue to remain the preferred partner for home medical equipment providers.

Industry Position

ResMed company overview shows a market-leading position in CPAP and cloud-enabled devices, supported by strong global sales and recurring mask and accessory revenue streams. The ResMed business model pairs hardware sales with subscription-like cloud services and data analytics to drive retention.

Market Reach

ResMed's products and services span CPAP flow generators, masks, ventilators, high-flow therapy, and portable oxygen concentrators, with presence in 120+ countries and strong OEM and DME channel relationships.

Key Risks

Primary risks include potential Medicare and international reimbursement changes that could compress margins, regulatory compliance costs, and competitive pressure in lower-cost device segments. Supply-chain disruptions and component inflation also pose operational risks.

Threats from Therapeutics

GLP-1 drug impact on obstructive sleep apnea prevalence has been moderated by current evidence, but long-term shifts in obesity-driven sleep apnea prevalence remain a strategic variable to monitor for demand risk.

Looking toward 2026 and beyond, ResMed technology explained emphasizes AI integration, expansion into COPD and broader respiratory care, and leveraging analytics to identify underserved patients and drive adoption of home-based therapies.

Future Outlook & Strategic Priorities

Management prioritizes AI-driven diagnostics, expansion of high-flow therapy and portable oxygen offerings, and targeted M&A funded by robust cash flow to accelerate a transition to a health-at-home platform.

• AI initiatives aim to increase diagnosis rates among hundreds of millions of undiagnosed sleep apnea sufferers globally.
• ResMed's respiratory care expansion targets COPD and home oxygen markets to diversify revenue beyond sleep devices.
• R&D and M&A funded by strong operating cash flow—2024 free cash flow margin near industry-leading levels—support product and software roadmaps.
• Maintaining cloud-connected device adoption preserves subscription-like revenue and strengthens competitive moat.

For additional context on corporate purpose and strategy, see Mission, Vision & Core Values of ResMed

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE